Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus

Vaccine

Volumn 29, Issue 48, 2011, Pages 8888-8897

  Santiago, Felix W ^a   Fitzgerald, Theresa ^a   Treanor, John J ^a   Topham, David J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antibody; B cells; Hemagglutinin; Immunology; Influenza virus; Vaccine

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT H5 HEMAGGLUTININ; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOMODULATION; IMMUNOREACTIVITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS IMMUNITY; VIRUS STRAIN;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CROSS PROTECTION; CROSS REACTIONS; DISEASE MODELS, ANIMAL; GENETIC DRIFT; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 82455188114     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.069     Document Type: Article

References (45)

1. Isolation of avian influenza A (H5N1) viruses from humans-Hong Kong, May-December 1997. MMWR Morb Mortal Wkly Rep 1997;46 (December (50)):1204-7.
2. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998, 279(January (5349)):393-396.
3. de Jong J.C., Claas E.C., Osterhaus A.D., Webster R.G., Lim W.L. A pandemic warning?. Nature 1997, 389(October (6651)):554.
4. WHO. H5N1 avian influenza: timeline of major events; 2010. Available from http://www.who.int/csr/disease/avian_influenza/ai_timeline/en/index.html.
5. WHO. Confirmed cases of avian influenza A (H5N1); 2010. Available from http://www.who.int/csr/disease/avian_influenza/country/en/.
6. de Jong M.D., Cam B.V., Qui P.T., Hien V.M., Thanh T.T., Hue N.B., et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005, 352(7):686-691.
7. de Jong M.D., Simmons C.P., Thanh T.T., Hien V.M., Smith G.J.D., Chau T.N.B., et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006, 12(10):1203-1207.
8. Gu J., Xie Z., Gao Z., Liu J., Korteweg C., Ye J., et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet 2007, 370(9593):1137-1145.
9. Buchy P., Mardy S., Vong S., Toyoda T., Aubin J-T., Miller M., et al. Influenza A/H5N1 virus infection in humans in Cambodia. J Clin Virol 2007, 39(3):164-168.
10. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008, 358(January (3)):261-273.
11. WHO. Continuing progress towards a unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses; 2009. Available from http://www.who.int/csr/disease/avian_influenza/guidelines/nomenclature/en/index.html.
12. Starick E., Beer M., Hoffmann B., Staubach C., Werner O., Globig A., et al. Phylogenetic analyses of highly pathogenic avian influenza virus isolates from Germany in 2006 and 2007 suggest at least three separate introductions of H5N1 virus. Vet Microbiol 2008, 128(April (3-4)):243-252.
13. Salzberg S.L., Kingsford C., Cattoli G., Spiro D.J., Janies D.A., Aly M.M., et al. Genome analysis linking recent European and African influenza (H5N1) viruses. Emerg Infect Dis 2007, 13(May (5)):713-718.
14. Kiss I., Gyarmati P., Zohari S., Ramsay K.W., Metreveli G., Weiss E., et al. Molecular characterization of highly pathogenic H5N1 avian influenza viruses isolated in Sweden in 2006. Virol J 2008, 5:113.
15. Ducatez M.F., Tarnagda Z., Tahita M.C., Sow A., de Landtsheer S., Londt B.Z., et al. Genetic characterization of HPAI (H5N1) viruses from poultry and wild vultures, Burkina Faso. Emerg Infect Dis 2007, 13(April (4)):611-613.
16. Nichol K.L., Treanor J.J. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006, 194(November (Suppl. 2)):S111-S118.
17. Fazekas de St G., Webster R.G. Disquisitions on original antigenic sin. II. Proof in lower creatures. J Exp Med 1966, 124(September (3)):347-361.
18. Fazekas de St G., Webster R.G. Disquisitions of original antigenic sin. I Evidence in man. J Exp Med 1966, 124(September (3)):331-345.
19. Kim J.H., Skountzou I., Compans R., Jacob J. Original antigenic sin responses to influenza viruses. J Immunol 2009, 183(September (5)):3294-3301.
20. Goji N.A., Nolan C., Hill H., Wolff M., Noah D.L., Williams T.B., et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008, 198(September (5)):635-641.
21. Baer J., Santiago F., Yang H., Wu H., Holden-Wiltse J., Treanor J., et al. B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant. Vaccine 2009, (November).
22. Smith K., Garman L., Wrammert J., Zheng N.Y., Capra J.D., Ahmed R., et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 2009, 4(3):372-384.
23. Treanor J. Recombinant proteins produced in insect cells. Curr Top Microbiol Immunol 2009, 333:211-225.
24. Powers D.C., Smith G.E., Anderson E.L., Kennedy D.J., Hackett C.S., Wilkinson B.E., et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis 1995, 171(June (6)):1595-1599.
25. Lakey D.L., Treanor J.J., Betts R.F., Smith G.E., Thompson J., Sannella E., et al. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis 1996, 174(October (4)):838-841.
26. Johansson B.E. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 1999, 17(April (15-16)):2073-2080.
27. Weldon W.C., Wang B-Z., Martin M.P., Koutsonanos D.G., Skountzou I., Compans R.W. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 2010, 5(9):e12466.
28. Hoffmann E., Lipatov A.S., Webby R.J., Govorkova E.A., Webster R.G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci U S A 2005, 102(September (36)):12915-12920.
29. Hannoun C., Megas F., Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004, 103(July (1-2)):133-138.
30. Hobson RLC D., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg 1972, 70:767-777.
31. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices MMWR Morb Mortal Wkly Rep 2010: 1-62.
32. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008, 3(1):e1401.
33. Khurana S., Verma S., Verma N., Crevar C.J., Carter D.M., Manischewitz J., et al. Bacterial HA1 vaccine against pandemic h5n1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J Virol 2011, 85(February (3)):1246-1256.
34. Brett I.C., Johansson B.E. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 2005, 339(September (2)):273-280.
35. Biesova Z., Miller M.A., Schneerson R., Shiloach J., Green K.Y., Robbins J.B., et al. Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus. Vaccine 2009, 27(October (44)):6234-6238.
36. Wei C.J., Xu L., Kong W.P., Shi W., Canis K., Stevens J., et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol 2008, 82(July (13)):6200-6208.
37. Belshe RB, Frey SE, Graham I, Mulligan MJ, Edupuganti S, Jackson LA, et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 2011;203(March (5)):666-73.
38. Suguitan A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006, 3(September (9)):e360.
39. Sabarth N., Howard M.K., Savidis-Dacho H., van Maurik A., Barrett P.N., Kistner O. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model. Vaccine 2010, 28(January (3)):650-656.
40. Bosch B.J., Bodewes R., de Vries R.P., Kreijtz J.H.C.M., Bartelink W., van Amerongen G., et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A (H1N1) influenza virus infection in ferrets. J Virol 2010, 84(October (19)):10366-10374.
41. Verbonitz M.W., Ennis F.A., Hicks J.T., Albrecht P. Hemagglutinin-specific complement-dependent cytolytic antibody response to influenza infection. J Exp Med 1978, 147(January (1)):265-270.
42. Hashimoto G., Wright P.F., Karzon D.T. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis 1983, 148(November (5)):785-794.
43. Tamura M., Webster R.G., Ennis F.A. Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry. Virology 1991, 182(May (1)):211-219.
44. Gulati U., Kumari K., Wu W., Keitel W.A., Air G.M. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine 2005, 23(11):1414-1425.
45. Wrammert J., Smith K., Miller J., Langley W.A., Kokko K., Larsen C., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453(7195):667-671.